{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:12:05Z","timestamp":1790860325244,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,1,7]],"date-time":"2010-01-07T00:00:00Z","timestamp":1262822400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s00228-009-0772-y","type":"journal-article","created":{"date-parts":[[2010,1,6]],"date-time":"2010-01-06T05:30:30Z","timestamp":1262755830000},"page":"383-386","source":"Crossref","is-referenced-by-count":38,"title":["CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity"],"prefix":"10.1007","volume":"66","author":[{"given":"Henrik","family":"Gr\u00e9en","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Skoglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Rommel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajaa A.","family":"Mirghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kourosh","family":"Lotfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,1,7]]},"reference":[{"key":"772_CR1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/0091270003262101","volume":"44","author":"B Peng","year":"2004","unstructured":"Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M et al (2004) Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 44:158\u2013162","journal-title":"J Clin Pharmacol"},{"key":"772_CR2","first-page":"935","volume":"8","author":"MH Cohen","year":"2002","unstructured":"Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A et al (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8:935\u2013942","journal-title":"Clin Cancer Res"},{"key":"772_CR3","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1124\/dmd.105.004283","volume":"33","author":"HP Gschwind","year":"2005","unstructured":"Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P et al (2005) Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 33:1503\u20131512","journal-title":"Drug Metab Dispos"},{"key":"772_CR4","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","volume":"44","author":"B Peng","year":"2005","unstructured":"Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879\u2013894","journal-title":"Clin Pharmacokinet"},{"key":"772_CR5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/jms.1002","volume":"41","author":"M Marull","year":"2006","unstructured":"Marull M, Rochat B (2006) Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple-quadrupole and linear ion trap mass spectrometers. J Mass Spectrom 41:390\u2013404","journal-title":"J Mass Spectrom"},{"key":"772_CR6","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022\u20134028","journal-title":"Blood"},{"key":"772_CR7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00280-003-0741-6","volume":"53","author":"P Coutre le","year":"2004","unstructured":"le Coutre P, Kreuzer KA, Pursche S, Bonin M, Leopold T, Baskaynak G et al (2004) Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 53:313\u2013323","journal-title":"Cancer Chemother Pharmacol"},{"key":"772_CR8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00003088-200544040-00002","volume":"44","author":"B Rochat","year":"2005","unstructured":"Rochat B (2005) Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet 44:349\u2013366","journal-title":"Clin Pharmacokinet"},{"key":"772_CR9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.gde.2008.01.004","volume":"18","author":"JA Engelman","year":"2008","unstructured":"Engelman JA, Settleman J (2008) Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 18:73\u201379","journal-title":"Curr Opin Genet Dev"},{"key":"772_CR10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0009-9236(99)70008-1","volume":"66","author":"RA Mirghani","year":"1999","unstructured":"Mirghani RA, Hellgren U, Westerberg PA, Ericsson O, Bertilsson L, Gustafsson LL (1999) The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. Clin Pharmacol Ther 66:454\u2013460","journal-title":"Clin Pharmacol Ther"},{"key":"772_CR11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0378-4347(00)00577-6","volume":"754","author":"RA Mirghani","year":"2001","unstructured":"Mirghani RA, Ericsson O, Cook J, Yu P, Gustafsson LL (2001) Simultaneous determination of quinine and four metabolites in plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 754:57\u201364","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"772_CR12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1600-0773.2003.pto930608.x","volume":"93","author":"H Green","year":"2003","unstructured":"Green H, Lotfi K, Zackrisson AL, Peterson C (2003) Spontaneous reversal of p-glycoprotein expression in multidrug resistant cell lines. Pharmacol Toxicol 93:297\u2013304","journal-title":"Pharmacol Toxicol"},{"key":"772_CR13","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90:850\u2013858","journal-title":"J Natl Cancer Inst"},{"key":"772_CR14","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clpt.2004.06.007","volume":"76","author":"RF Frye","year":"2004","unstructured":"Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ (2004) Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 76:323\u2013329","journal-title":"Clin Pharmacol Ther"},{"key":"772_CR15","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00280-003-0722-9","volume":"53","author":"AE Bolton","year":"2004","unstructured":"Bolton AE, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U et al (2004) Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 53:102\u2013106","journal-title":"Cancer Chemother Pharmacol"},{"key":"772_CR16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00280-004-0832-z","volume":"54","author":"C Dutreix","year":"2004","unstructured":"Dutreix C, Peng B, Mehring G, Hayes M, Capdeville R, Pokorny R et al (2004) Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 54:290\u2013294","journal-title":"Cancer Chemother Pharmacol"},{"key":"772_CR17","doi-asserted-by":"crossref","first-page":"7102","DOI":"10.1158\/1078-0432.CCR-08-0950","volume":"14","author":"A Petain","year":"2008","unstructured":"Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, Geoerger B et al (2008) Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 14:7102\u20137109","journal-title":"Clin Cancer Res"},{"key":"772_CR18","first-page":"625","volume":"9","author":"C Gambacorti-Passerini","year":"2003","unstructured":"Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S et al (2003) Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 9:625\u2013632","journal-title":"Clin Cancer Res"},{"key":"772_CR19","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","volume":"108","author":"L Roy","year":"2006","unstructured":"Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA et al (2006) Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 108:1478\u20131484","journal-title":"Blood"},{"key":"772_CR20","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","volume":"113","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D et al (2009) Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113:6315\u20136321","journal-title":"Blood"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0772-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-009-0772-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-009-0772-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T08:52:04Z","timestamp":1558687924000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-009-0772-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,7]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["772"],"URL":"https:\/\/doi.org\/10.1007\/s00228-009-0772-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,7]]}}}